1.49
+0(+0.00%)
Currency In USD
| Previous Close | 1.49 |
| Open | 1.48 |
| Day High | 1.49 |
| Day Low | 1.46 |
| 52-Week High | 2.55 |
| 52-Week Low | 1.12 |
| Volume | 2,416 |
| Average Volume | 14,727 |
| Market Cap | 73.08M |
| PE | -6.48 |
| EPS | -0.23 |
| Moving Average 50 Days | 1.48 |
| Moving Average 200 Days | 1.72 |
| Change | 0 |
If you invested $1000 in MediciNova, Inc. (MNOV) 10 years ago, it would be worth $368.81 as of May 09, 2025 at a share price of $1.49. Whereas If you bought $1000 worth of MediciNova, Inc. (MNOV) shares 5 years ago, it would be worth $279.55 as of May 09, 2025 at a share price of $1.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
GlobeNewswire Inc.
Apr 14, 2025 11:00 PM GMT
LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
GlobeNewswire Inc.
Apr 08, 2025 11:00 PM GMT
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
GlobeNewswire Inc.
Dec 05, 2024 11:00 PM GMT
LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study up